Centerphase has entered into a collaboration with Mayo Clinic to speed the introduction of new medical treatments developed by the biopharmaceutical industry. The Company addressed the root causes historically plaguing the clinical trials process: the lack of a systematic, structured approach for evaluating and optimizing protocols and the tremendous burdens associated with trial start-up administration.
Clinical testing of new medical therapies is an arduous process, which is difficult to plan, costly and habitually delayed. The industry spends over $30 billion a year on clinical trials, yet nearly 90% of trials fail to meet their timelines or budgets. The result has been longer delivery times and great disappointment among patients researchers and clinical trial sponsors.
"Centerphase couples its proprietary methodologies and technologies with Mayo Clinic's medical and informatics expertise, to create a unique solution that we expect will greatly accelerate clinical trial performance," stated Gary Lubin, President and CEO of the new company. "Centerphase is the first independent clinical trials office and seeks to build on its relationship with Mayo Clinic by collaborating with select academic medical centers and healthcare networks."